Richmond Pharmacology is a leading clinical research organization (CRO) specializing in clinical studies. With a full range of services, they offer expertise in adaptive, TQT, and bridging studies, as well as patient recruitment. Their mission is to accelerate drug development timelines, ultimately saving lives.

Their team of experts, including influential clinical leaders, work closely with sponsors to create adaptive and integrated protocols, reducing drug development timelines. Richmond Pharmacology operates a state-of-the-art facility in London, adjacent to Guy's Hospital, where they deliver their specialist services. The facility includes dedicated patient wards that meet the highest safety standards to ensure participant comfort.

As an MHRA accredited Phase I unit, Richmond Pharmacology adheres to the highest clinical and ethical standards. They have access to a diverse and expanding volunteer database, allowing for a broad range of patient populations across various diseases. With a history spanning two decades, Richmond Pharmacology has evolved from small molecules to the cutting-edge fields of RNA therapeutics and gene editing.

They continue to prioritize clinical excellence and remain committed to advancing research in under-researched areas